The BioIndustry Association announces 2021 charity partnership with Ovarian Cancer Action

The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovarian cancer does today.

CTI Clinical Trial & Consulting Recognized as a Top Enrolling Site in Janssen's ENSEMBLE Phase 3 COVID-19 Vaccine Trial

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces that their research site was one of the top enrolling sites for the Janssen Pharmaceutical Companies of Johnson & Johnson’s large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735. Johnson & Johnson announced the Phase 3 trial reached full enrollment in December.

Guest Blog | All data matters and all matters data – how Health Data Research hubs are unlocking the power of data

In September this year, the seven initial Health Data Research Hubs celebrated their joint first birthday and reflected on their achievements over the past year. Set up as part of a four-year, £37 million investment from the UK Government Industrial Strategy Challenge Fund, the data hubs were designed to create a UK-wide system for the safe and responsible use of health-related data on a large scale.

Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program

Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary. 

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

• Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration • Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development

CEO Update | Monday 11 January

This week’s CEO blog covers the largest acquisition of a privately listed UK biotech company on record, new positive analysis of biotech stocks, our preparations for the J.P. Morgan Healthcare conference, the latest on COVID-19 vaccinations and a look ahead to our first virtual event of the year based on work of member companies in the North West of England.

UK in spotlight at JP Morgan Healthcare conference 2021 with the largest acquisition of a privately listed UK biotech company on record

The largest acquisition of a private UK biotech company on record has been announced today, as the curtain raiser to the JP Morgan global Healthcare conference, with the news that Sanofi has acquired Kymab for $1.1bn with the possibility of further $350m milestone payments.

US investors flock to UK biotech as sector delivers strong outperformance in a turbulent 2020

Biotech companies on London stock markets delivered market-beating returns in 2020 and attracted new investors looking for growth in a turbulent year, according to new analysis published today by the UK BioIndustry Association (BIA) and Radnor Capital Partners.

BIA responds to publication of Rare Disease framework

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “We are very encouraged by the publication of the Rare Disease Framework and in particular its focus on ensuring patient access to treatments. Science continues to advance and to deliver new treatments for rare diseases where no treatment has been available before.

Abzena announces opening of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena, a Global Partner Research Organization for integrated bench to market solutions for biologics and bioconjugates, has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas.